FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

MISSION

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)					2 Issuer Name and Ticker or Trading Symbol						5. Relationship of Reporting Person(s) to Issuer				
Name and Address of Reporting Person – Welch David F				2. Issuer Name and Ticker or Trading Symbol CytoDyn Inc. [CYDY]						S. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
(Last) (First) (Middle) 1111 MAIN STREET, SUITE 660				3. Date of Earliest Transaction (Month/Day/Year) 01/10/2019											
(Street)					4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) X Form filed by One Reporting Person				
VANCOUVER, WA 98660										Form filed by More than One Reporting Person					
(Cit	ty)	(State)	(Zip)			Table I	- Non-Deriv	ative Securities	Acquired,	Dispose	d of, or Ben	neficially Own	ed		
(Instr. 3) Date			2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Data r) any (Month/Day/Y		(Instr. 8)		. Securities Acq A) or Disposed of Instr. 3, 4 and 5) (A) or (D)	of (D) Owr Tran	Owned Following Reported Transaction(s) (Instr. 3 and 4)			wnership orm: B irect (D) O	. Nature f Indirect geneficial ownership (nstr. 4)	
Reminder:	Report on a	separate line for ea	ch class of securitie	s benefici	allv ow	ned direct	tlv or indired	etly.							
							Persor contail	ns who respor ned in this for isplays a curr	m are not	require	d to respo	nd unless th		174 (9-02)	
						-		osed of, or Beno invertible secur	•	vned					
1. Title of Derivative Security (Instr. 3)	Conversion	3. Transaction Date (Month/Day/Year	3A. Deemed Execution Date, i) any (Month/Day/Year	f Transaction Code (Instr. 8)		Number erivative curities equired) or sposed of) estr. 3, 4, d 5)	Expiration (Month/D	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Form of Derivative Security: Direct (D) or Indirect	(Instr. 4)	
				Code	v	(A) (D	Date Exercisable	Expiration le Date	Title	Amount or Number of Shares					
Stock Option (right to buy)	\$ 0.5	01/10/2019		A	38	3,904	<u>(1)</u>	01/10/2029	Common Stock	38,904	\$ 0	38,904	D		
Repoi	rting O	wners													
Reporting Owner Name / Address															
		ET, SUITE 660 A 98660	Director 10% Ow X	oner Offic	cer Ot	ner									
Signa	tures														

Explanation of Responses:

/s/ Michael D. Mulholland, as attorney-in-fact

**Signature of Reporting Person

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The option will vest commencing on March 1, 2019 with respect to 13,904 shares and on June 1, 2019 with respect to 25,000 shares.

01/14/2019

Date


Remarks:

Exhibit List:

Exhibit 24 - Power of Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.



POWER OF ATTORNEY

The undersigned hereby appoints each of Michael D. Mulholland, Steven M. Skolnick, James O'Grady and Bettina Elstroth, signing singly, as the undersigned's true and lawful attorney-in-fact to:

- 1. Execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of CytoDyn Inc. (the "Company"), Forms 3, 4, and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder, and any other forms or reports the undersigned may be required to file in connection with the undersigned's ownership, acquisition, or disposition of securities of the Company, including forms required to generate codes for the Securities and Exchange Commission's electronic filing system; and
- 2. Do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5, or other form or report, and timely file such form or report with the United States Securities and Exchange Commission and any stock exchange or similar authority as appropriate.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing necessary or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned could do if personally present, hereby ratifying and confirming all that such attorney-in-fact shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys- in-fact, in serving in such capacity at the request of the undersigned, are not assuming, and the Company is not assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer subject to Section 16 of the Securities Exchange Act of 1934 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-infact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 10th day of January, 2019.

/s/ David F. Welch
Signature

David F. Welch, Ph.D.
Print Name